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Abstract
Background: Invasive infection with Streptococcus pneumoniae (pneumococci) causes significant
morbidity and mortality. Case series and experimental data have shown that the capsular serotype
is involved in the pathogenesis and a determinant of disease outcome.
Methods: Retrospective review of 464 cases of invasive disease among adults diagnosed between
1990 and 2001. Multivariate Cox proportional hazard analysis.
Results: After adjustment for other markers of disease severity, we found that infection with
serotype 3 was associated with an increased relative risk (RR) of death of 2.54 (95% confidence
interval (CI): 1.22–5.27), whereas infection with serotype 1 was associated with a decreased risk
of death (RR 0.23 (95% CI, 0.06–0.97)). Additionally, older age, relative leucopenia and relative
hypothermia were independent predictors of mortality.
Conclusion: Our study shows that capsular serotypes independently influenced the outcome
from invasive pneumococcal disease. The limitations of the current polysaccharide pneumococcal
vaccine warrant the development of alternative vaccines. We suggest that the virulence of
pneumococcal serotypes should be considered in the design of novel vaccines.
Background
Streptococcus pneumoniae (pneumococci) is a leading cause
of pneumonia, sepsis, and meningitis among adults. Mor-
tality associated with invasive disease remains high at 5–
35% depending on site of infection, age and comorbidity
[1-4].
Ninety different capsular serotypes cause disease among
humans but less than 30 types account for the majority
(>90%) of invasive cases [5]. The capsular polysaccharide
plays an important role in pneumococcal pathogenesis,
e.g. its diversity allowed for immune evasion by prevent-
ing phagocytosis in non-immune individuals [6], the
amount of capsular polysaccharide correlated with pneu-
mococcal virulence [7,8], during experimental pneumo-
cocal meningitis serotypes 3, 6B, 14, 23F caused more
severe meningeal inflammation than serotypes 1, 5, 9 and
7F [9,10]. and in a murine model of pneumococcal sepsis
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certain serotypes were more lethal than others [11]. In
adult case series, unadjusted mortality rates from invasive
disease were increased with serotypes 3 and 5 while infec-
tion with serotypes 1, 4, 9V 12F and 14 were associated
with lower mortality rates [12-16].
Currently, a polysaccharide pneumococcal vaccine is rec-
ommended for elderly adults because it has been demon-
strated to prevent invasive pneumococcal disease [17-20]
However, the vaccine is unable to prevent non-bacteremic
pneumonia. Future vaccine developments for adults are
likely to be based on conjugate-polysaccharides and we
believe that differences in serotype-specific mortality
could be important to consider when including capsular
serotypes.
The aim of the current study was to study serotype-specific
mortality after adjustment for other factors associated
with outcome.
Methods
Subjects
464 adult patients older than 16 years with first episodes
of bacteremic pneumococcal disease diagnosed between
January 1990 and January 2001 at Hvidovre University
Hospital, Copenhagen were included. Cases were identi-
fied from the records of the Department of Clinical
Microbiology.
Microbiology
Identification of S. pneumoniae and susceptibility testing
for penicillin was done by the Department of Clinical
Microbiology. All isolates were serotyped by the Quellung
reaction at the Streptococcal Laboratory, Statens Serum
Institute (SSI), Copenhagen, by using type-specific pneu-
mococcal rabbit antisera [5]. Antimicrobial susceptibility
testing was performed first as a screening with the agar
disk diffusion test using oxacillin (1-µg disk; AB Biodisk,
Solna, Sweden) and erythromycin (78 µg, Neo-Sensitabs;
Rosco, Copenhagen, Denmark) on 10% horse blood agar
plates (SSI). Isolates with reduced sensitivity against oxa-
cillin or erythromycin were further characterized by deter-
mining the minimal inhibitory concentration (MIC) of
penicillin, erythromycin, ceftriaxone, and ciprofloxacin
by using the E-test (AB Biodisk) on resistance plates (4.6
mm; SSI).
Covariates
Data were extracted from patient records using a standard-
ized data collection form. Information was collected at
the time of diagnosis and included age, sex, site of infec-
tion, comorbidity, smoking status, alcoholism, splenec-
tomy, residence, injection drug use, blood chemistry and
in-hospital mortality. Comorbidity consisted of any of the
following: chronic lung disease, chronic heart disease,
chronic renal disease, chronic liver disease, diabetes mel-
litus, cancer, autoimmune disease, human immunodefi-
ciency virus (HIV) infection, and 'other chronic diseases'.
Alcoholism was defined as known abuse. Smoking was
considered in two categories: never or ever. Results of
chest roentgenograms were obtained and the presence of
pulmonary infiltrates or pleural effusions noted.
Statistics
All values are expressed as median and interquartile range.
Differences between groups were estimated by χ2 statistics
(Fisher's exact or Pearson's test, as appropriate). Survival
curves were constructed by the method of Kaplan-Meier
and compared by the log rank test. Relative risk (RR) with
the 95% confidence interval (CI) for progression to death
was estimated using univariate and multivariate Cox pro-
portional hazard regression models. All variables with >
80% of values available were tested in univariate analysis
and all variables with a P value less than 0.1 were entered
in the multivariate analysis. Subjects with more than one
episode of pneumococcal bacteremia were right censored,
i.e. only their first episode was included in the analysis.
Statistical analyses were done using the Statistical Package
for Social Sciences (version 11.0; SPSS; Chicago, IL).
Results
Patient characteristics
464 individual cases of invasive pneumococcal disease
were identified. Baseline characteristics are given in table
1.
There were 123 deaths during hospitalization resulting in
an in-hospital mortality rate of 26.5% (95% CI: 21.8–
31.2%). 110 of 410 (26.8%) patients with a typed isolate
died compared to 13 of 54 (24.1%) of patients without a
typed isolate (P = 0.724). 51 (11.0%) patients required
mechanical ventilation. Only five patients had a record of
pneumococcal vaccination. In univariate analysis, survi-
vors were younger, had less comorbidity, fewer had
reported alcoholism, and had higher total blood leuko-
cyte counts and temperature on admission (table 1). After
multivariate analysis, increasing age, low temperature and
a leukocyte count less than 9 × 109/L remained signifi-
cantly associated with in-hospital mortality (table 3).
Capsular serotype and survival
37 different types were identified among 410 typed iso-
lates (table 2). Two isolates could not be typed and were
considered 'rough'. Mortality varied between serotype
groups with type 3 having the highest unadjusted in-hos-
pital mortality (50%). In contrast, the unadjusted mortal-
ity rates were between 0 and 10 % for serotypes 1, 6A and
20. Each serotype was entered separately in a Cox regres-
sion analysis and compared to all other cases. Only sero-BMC Infectious Diseases 2004, 4:21 http://www.biomedcentral.com/1471-2334/4/21
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types 1 and 3 were significantly associated with in-
hospital mortality. For the multivariable analysis, all types
other than serotype 1 and 3 served as the reference group.
Serotype 1 and 3 remained independently associated with
mortality after adjusting for age, comorbidity, alcoholism,
temperature and leukocyte count (table 3 and figure 1).
Analysis of outcome by primary focus
Pneumococcal bacteremic pneumonia
310 patients had a pulmonary focus. Of these, 84 (27.1%)
died during hospitalization. 33 (10.6%) required
mechanical ventilation. In univariate analysis, presence of
a bilateral infiltrate was associated with an increased mor-
tality (2.54 (1.60–4.03)) compared to a unilateral infil-
trate, whereas the presence of an effusion was not. 235
patients with complete data were available for multivari-
ate analysis. In this analysis, a bilateral infiltrate, age, alco-
holism and leukocyte count were independently
associated with mortality. Serotype 1 and 3 showed a
trend towards an association with outcome at a signifi-
cance level of 0.06 for both.
Pneumococcal bacteremia with unknown focus
96 patients had S. pneumoniae isolated from blood with-
out a known focus. 34 (35.4%) patients died. Nine cases
were caused by serotype 3 and of these six died. Five cases
were caused by serotype 1. None of these were fatal. In
univariate analysis, serotype 3 remained associated with
Table 1: Patient characteristics
Mortality rate, % Survivors No. (%) Non-survivors No. (%) P value
Age, years
18–49 17.8 83 (25.9) 18 (14.6)
50–65 33.8 47 (14.5) 24 (19.6)
65–79 29.6 114 (35.5) 48 (39.0)
> 80 30.0 77 (24.0) 33 (26.8) 0.077
Sex
Female 29.4 199 (58.4) 64 (52.0)
Male 24.3 142 (41.6) 59 (48.0) 0.244
Focus
Bacteremia 35.4 62 (20.5) 34 (27.6)
Pneumonia 27.1 226 (74.8) 84 (68.3)
Meningitis 44.4 5 (1.7) 4 (0.8)
Otitis media 10.0 9 (3.0) 1 (3.3) 0.153
Comorbidity*
No 23.6 133 (43.8) 41 (33.3)
Yes 32.4 171 (56.2) 82 (66.7) 0.047
Alcoholism
No 27.0 265 (87.2) 98 (79.7)
Yes 39.1 39 (12.8) 25 (20.3) 0.049
Smoking status
Never 27.1 70 (29.8) 26 (33.3)
Current or former 24.0 165 (70.2) 52 (66.7) 0.573
Splenectomy
No 28.6 300 (98.7) 120 (97.6)
Yes 42.9 4 (1.3) 3 (2.4) 0.416
Intravenous drug use
No 29.4 293 (96.4) 122 (99.2)
Yes 8.3 11 (3.6) 1 (0.8) 0.193
Nursing home residence
Yes 27.6 21 (7.7) 8 (7.1)
No 27.2 279 (92.3) 104 (92.9) 0.984
Temperature
≥ 38.5°C 22.8 210 (71.9) 62 (56.4)
< 38.5°C 36.9 82 (28.1) 48 (43.6) 0.003
B-leukocytes
> 9 109/L 24.7 216 (81.8) 71 (65.7)
≤ 9 109/L 43.5 48 (18.2) 37 (34.3) 0.001
*: includes patients with chronic lung disease, chronic heart disease, chronic renal disease, chronic liver disease, diabetes mellitus, cancer, 
autoimmune disease, human immunodeficiency virus (HIV) infection, and 'other chronic diseases'. Patients may have more than one comorbidity.BMC Infectious Diseases 2004, 4:21 http://www.biomedcentral.com/1471-2334/4/21
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Table 2: Streptococcus pneumoniae capsular serotype associated mortality.
Serotype No. (% of total) Mortality (%)
1 46 (10.1) 4 (8.7)
3 24 (5.3) 12 (50)
4 49 (10.8) 11 (22.4)
6A 10 (2.2) 1 (10)
6B 12 (2.6) 5 (41.7)
7F 22 (4.8) 3 (13.6)
8 22 (4.8) 5 (22.7)
9N 13 (2.9) 4 (28.6)
9V 22 (4.8) 9 (39.1)
12F 18 (4.0) 5 (27.8)
14 37 (8.1) 9 (24.3)
19A 10 (2.2) 5 (50)
19F 12 (2.6) 4 (30.8)
20 14 (3.1)
23F 15 (3.3) 5 (31.2)
5, 10A, 10F, 11A, 12A, 15A, 15B, 16F, 17F, 18C, 22F, 23A, 
23B, 24F, 29, 33F, 34, 35F, 36, 38, 42, 48 and 'rough'
74 (15.9) 27 (36.5)
Not typed 54 (11.2) 13 (24.1)
Total 464 (100) 123 (26.5)
Table 3: Multivariate analysis of risk factors associated with in-hospital death from invasive pneumococcal infection
Univariate RR (95% CI) Multivariate RR (95% CI)*
Serotype
Other 1.0 1.0
Type 3 2.14 (1.17–3.91) 2.54 (1.22–5.27)
Type 1 0.29 (0.11–0.77) 0.23 (0.06–0.97)
Age, years
18–49 1.0 1.0
50–65 2.00 (1.08–3.68) 2.23 (1.00–4.97)
65–79 1.74 (1.01–2.99) 3.20 (1.50–6.81)
> 80 1.79 (1.01–3.18) 2.86 (1.23–6.65)
Comorbidity**
No 1.0 1.0
Yes 1.44 (0.99–2.10) 1.24 (0.78–2.00)
Alcoholism
No 1.0 1.0
Yes 1.55 (1.00–2.40) 1.82 (0.97–3.42)
B-leukocyte count
> 9 109/L 1.0 1.0
≤ 9 109/L 2.07 (1.39–3.08) 2.76 (1.66–4.59)
Temperature
≥ 38.5°C 1.0 1.0
< 38.5°C 1.79 (1.23–2.61) 1.67 (1.07–2.62)
*: Cox regression with all variables forced into the model. RRs are adjusted with all variables included in the model. **: includes patients with 
chronic lung disease, chronic heart disease, chronic renal disease, chronic liver disease, diabetes mellitus, cancer, autoimmune disease, human 
immunodeficiency virus (HIV) infection, and 'other chronic diseases'. Patients may have more than one comorbidity.BMC Infectious Diseases 2004, 4:21 http://www.biomedcentral.com/1471-2334/4/21
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outcome (RR: 2.49, 95% CI: 1.02–6.10). In this subanal-
ysis, leukocyte count was the only other variable associ-
ated with outcome by univariate analysis. Both remained
significantly associated with outcome in multivariate
analysis: serotype 3 (3.00 (1.12–8.08)) and leukocyte
count less than 9 (4.15 (1.70–10.16)).
Pneumococcal meningitis and otitis media
Among nine cases of meningitis, none were caused by
serotypes 1 and 3. Serotypes 4, 6B, 8, 10A, 12F, 14, and
19F accounted for one case each and serotype 24F for two
cases.
Only ten cases of bacteremic otitis media were detected
and of these, one case was caused by serotype 3. The
patient survived. None were caused by serotype 1. Sero-
types 4, 6A, 11A, 19A, 23F accounted for one case each
and serotype 7F and 20 caused two cases each.
Antibiotic susceptibility
Five isolates (0.9%) had reduced susceptibility to penicil-
lin. Only one isolate (serotype 14) had a MIC of penicillin
≥ 2 µg/ml. This patient survived but one patient with
intermediate resistance died. Four isolates (serotypes 5,
9V, 14 and 19F) had an MIC of > 0.064 and < 2 µg/ml.
Reduced susceptibility to erythromycin (MIC ≥ 4 µg/ml)
was detected in 10 isolates (2.2%). Three of these patients
died.
Discussion
In this study we show that pneumococcal capsular sero-
types 1 and 3 predicted outcome from invasive disease
regardless of age and other markers of disease severity.
Additionally, we show that age and an inability to mount
a rise in temperature or peripheral leukocytes independ-
ently predicted mortality.
Varying and complex repeating units of polysaccharide
permit a large diversity among pneumococci. It has been
known for decades that the capsule per se and the amount
of capsule were necessary components of pneumococcal
virulence [7,8]. Early work showed that the increased con-
tent of capsular polysaccharide of some pneumococci
(e.g. serotype 3) increased resistance to phagocytosis
[7,8]. Several groups have demonstrated that serotypes
with high polysaccharide content generally were more
lethal in murine models of sepsis than serotypes with
lower polysaccharide content [11,12,22]. In addition, cell
wall components and toxins (e.g. pneumolysin,
autolysin, peptidoglycan and lipoteichoic acid) are
thought to play a role in the inflammatory response dur-
ing pneumococcal infection [23-25]. Whether the genetic
background, the capsular type or both confer virulence is
a matter of debate. Certainly the genetic background of
the recipient strain plays a role since capsule transformed
strains do not necessarily acquire the virulence of the
donor strain [26]. Further, pneumococci switch capsules
so strains with the same genetic background have heterol-
ogous capsular types and vice versa [27-29]. Henriques et
al. studied clonality among serotype 3 and found that 24
of 29 strains were comprised of just two molecular pat-
terns suggesting a close clonal relationship whereas other
capsular types typically had several molecular patterns
[16]. Unfortunately, molecular patterns were not studied
in the present study. Future studies should investigate the
prognostic value of molecular patterns as compared to
capsular types.
As in numerous studies, increasing age [1,12,15,30,31],
low temperature [32] and leucopenia [12,15,32,33] were
factors associated with death from invasive disease
although only few of these factors have been studied by
multivariate analysis. Among patients with bacteremic
pneumococcal pneumonia, we confirm that bilateral
infiltrates increased the risk of death [32,34]. We did not
find any association between smoking, nursing home res-
idence, intravenous drug use, alcoholism, or comorbidity
and risk of death. Mortality rates were comparable to stud-
ies published within the past 40 years [1,12-15,32,33,35].
Few patients had resistant strains and decreased suscepti-
Cumulative survival according to serotype (log rank test: P =  0.066) Figure 1
Cumulative survival according to serotype (log rank test: P = 
0.006).
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bility to penicillin or erythromycin did not appear to
influence outcome in this study.
Observational and case-control studies have shown that
polysaccharide vaccination reduced the risk of invasive
pneumococcal disease by approximately 60% among the
elderly [17-20]. Less than 1% of our cohort had a record
of pneumococcal vaccination in spite of a serotype cover-
age rate greater than 90%. However, the vaccine was intro-
duced for general use for elderly people late (1996) in
Denmark. Lack of efficacy against non-bacteremic pneu-
mococcal pneumonia and the need for regular re-immu-
nization remain a matter of concern. Therefore,
alternative vaccine formulations for adults need to be
evaluated. Recently, the introduction of a 7-valent conju-
gate vaccine has lead to a decrease in pneumococcal dis-
ease among children in the United States [36]. A 9-valent
conjugate vaccine was shown to protect children against
pneumonia and invasive disease [37]. Since the epidemi-
ology of pneumococcal disease is different among adults,
a conjugate vaccine would have to be composed differ-
ently in order to achieve acceptable coverage. In general,
the frequency of serotypes recovered from invasive disease
have been used to guide the development of pneumococ-
cal vaccines although such an approach does not necessar-
ily reflect the potential of a serotype to cause life-
threatening disease. Conjugate vaccines are limited in the
range of covered serotypes because of space constraints. In
the Danish population the eleven most frequent serotypes
(1, 3, 4, 6B, 7F, 8, 9N, 9V, 12F, 14 and 23F) account for
74% of invasive infections among adults and the thirteen
most frequent (5 and 19F) account for 80% [5]. In this
study, the current 7-valent conjugate would have a poten-
tial coverage rate of only 38%. In light of the current
study, the life-threatening potential of a serotype should
be taken into account when selecting serotypes for an
adult conjugate vaccine. Larger studies are needed in order
to rank serotypes accordingly.
This study has limitations because of its retrospective
design. Several variables were unavailable from a number
of cases leading to decreased statistical power of the mul-
tivariate analysis and possible introduction of bias. How-
ever, it is unlikely that there are any systematic differences
between cases included in the final model and cases that
were excluded.
Conclusion
Our study shows that capsular serotypes influence the
outcome from invasive pneumococcal disease. The limita-
tions of the current polysaccharide vaccine warrant the
development of alternative vaccines such as a conjugate
vaccine that may protect against non-bacteremic
pneumonia [37]. We suggest that the virulence of pneu-
mococcal serotypes should be considered in the design of
novel vaccines.
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